What is Viracta Therapeutics Inc's earnings per share (EPS)?

Viracta Therapeutics Inc (VIRX) reported diluted earnings per share of $-1.32 for fiscal year 2023. This represents a -1.5% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Viracta Therapeutics Inc Financials

VIRX

Source SEC Filings (10-K/10-Q) Updated Sep 30, 2024 Currency USD FYE December

This page shows Viracta Therapeutics Inc (VIRX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

2/9

Viracta Therapeutics Inc passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.78x

For every $1 of reported earnings, Viracta Therapeutics Inc generates $0.78 in operating cash flow (-$39.9M OCF vs -$51.1M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-13.7x

Viracta Therapeutics Inc earns $-13.7 in operating income for every $1 of interest expense (-$50.7M vs $3.7M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

-$50.2M

YoY+0.4%

Viracta Therapeutics Inc's EBITDA was -$50.2M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 0.4% from the prior year.

Net Income

-$51.1M

YoY-3.8%

Viracta Therapeutics Inc reported -$51.1M in net income in fiscal year 2023. This represents a decrease of 3.8% from the prior year.

EPS (Diluted)

$-1.32

YoY-1.5%

Viracta Therapeutics Inc earned $-1.32 per diluted share (EPS) in fiscal year 2023. This represents a decrease of 1.5% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$40.0M

YoY-12.8%

Viracta Therapeutics Inc generated -$40.0M in free cash flow in fiscal year 2023, representing cash available after capex. This represents a decrease of 12.8% from the prior year.

Cash & Debt

$12.3M

YoY-66.5%

5Y CAGR-2.1%

10Y CAGR-2.0%

Viracta Therapeutics Inc held $12.3M in cash against $0 in long-term debt as of fiscal year 2023.

Dividends Per Share

N/A

Shares Outstanding

39M

YoY+2.0%

Viracta Therapeutics Inc had 39M shares outstanding in fiscal year 2023. This represents an increase of 2.0% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-278.7%

YoY-198.2pp

Viracta Therapeutics Inc's ROE was -278.7% in fiscal year 2023, measuring profit generated per dollar of shareholder equity. This is down 198.2 percentage points from the prior year.

Capital Allocation

R&D Spending

$33.4M

YoY+27.1%

5Y CAGR+18.0%

10Y CAGR+1.5%

Viracta Therapeutics Inc invested $33.4M in research and development in fiscal year 2023. This represents an increase of 27.1% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$138K

YoY+206.7%

Viracta Therapeutics Inc invested $138K in capex in fiscal year 2023, funding long-term assets and infrastructure. This represents an increase of 206.7% from the prior year.

VIRX Income Statement

Metric	FY23	FY22	FY21	FY20	FY19	FY18
Revenue	N/A	N/A	N/A	$120K-94.2%	$2.1M+774.7%	$237K
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$33.4M+27.1%	$26.3M+10.1%	$23.9M+77.2%	$13.5M+51.9%	$8.9M-39.3%	$14.6M
SG&A Expenses	$17.3M-28.8%	$24.3M+57.6%	$15.4M+188.6%	$5.3M+67.4%	$3.2M-71.8%	$11.3M
Operating Income	-$50.7M-0.2%	-$50.6M+55.7%	-$114.3M-507.4%	-$18.8M+19.2%	-$23.3M+9.4%	-$25.7M
Interest Expense	$3.7M+541.9%	$577K+17.5%	$491K+127.3%	$216K+404.5%	$43K-96.3%	$1.2M
Income Tax	$0	$0	$0	$0	$0	$0
Net Income	-$51.1M-3.8%	-$49.2M+57.1%	-$114.8M-503.5%	-$19.0M-40.3%	-$13.6M+49.1%	-$26.6M
EPS (Diluted)	$-1.32-1.5%	$-1.30+63.9%	$-3.60	N/A	N/A	N/A

Metric	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$7.2M+9.7%	$6.5M-34.2%	$10.0M	N/A	$8.2M-0.5%	$8.2M+7.8%	$7.6M	N/A
SG&A Expenses	$3.0M-1.2%	$3.0M-22.4%	$3.9M	N/A	$4.3M+1.5%	$4.3M-7.5%	$4.6M	N/A
Operating Income	-$10.2M-6.2%	-$9.6M+30.9%	-$13.9M	N/A	-$12.5M-0.2%	-$12.4M-2.0%	-$12.2M	N/A
Interest Expense	$679K-2.6%	$697K-18.8%	$858K	N/A	$953K+3.5%	$921K+4.7%	$880K	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$10.6M-7.4%	-$9.8M-7.5%	-$9.1M	N/A	-$12.6M-0.9%	-$12.5M-2.3%	-$12.2M	N/A
EPS (Diluted)	$-0.27-8.0%	$-0.25-8.7%	$-0.23	N/A	$-0.33-3.1%	$-0.320.0%	$-0.32	N/A

VIRX Balance Sheet

Metric	FY23	FY22	FY21	FY20	FY19	FY18
Total Assets	$56.7M-40.9%	$96.0M-11.6%	$108.6M+124.7%	$48.3M+161.9%	$18.4M+20.4%	$15.3M
Current Assets	$55.0M-41.4%	$93.7M-10.9%	$105.3M+123.0%	$47.2M+157.9%	$18.3M+20.4%	$15.2M
Cash & Equivalents	$12.3M-66.5%	$36.8M-64.5%	$103.6M+119.9%	$47.1M+158.5%	$18.2M+33.0%	$13.7M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$38.4M+10.0%	$34.9M+146.0%	$14.2M-85.0%	$94.5M+101.8%	$46.8M+50.2%	$31.2M
Current Liabilities	$38.4M+283.3%	$10.0M+10.2%	$9.1M+44.6%	$6.3M+162.5%	$2.4M-78.9%	$11.3M
Long-Term Debt	$0-100.0%	$24.9M+416.2%	$4.8M+16.0%	$4.2M	N/A	N/A
Total Equity	$18.3M-70.0%	$61.1M-35.3%	$94.4M+304.3%	-$46.2M-62.8%	-$28.4M-79.0%	-$15.9M
Retained Earnings	-$265.9M-23.8%	-$214.9M-29.7%	-$165.7M-225.4%	-$50.9M-59.6%	-$31.9M+95.2%	-$659.5M

Metric	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22
Total Assets	$22.0M-29.9%	$31.3M-24.2%	$41.3M-27.1%	$56.7M-14.7%	$66.4M-13.6%	$76.9M-10.4%	$85.8M-10.6%	$96.0M
Current Assets	$21.8M-29.8%	$31.1M-24.1%	$41.0M-25.5%	$55.0M-14.7%	$64.4M-13.6%	$74.6M-10.6%	$83.4M-11.0%	$93.7M
Cash & Equivalents	$13.1M-6.1%	$14.0M+15.9%	$12.1M-2.1%	$12.3M-4.2%	$12.9M-10.1%	$14.3M-21.0%	$18.1M-50.8%	$36.8M
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$28.6M-0.3%	$28.7M-5.3%	$30.3M-21.2%	$38.4M+5.3%	$36.4M+1.0%	$36.1M+4.1%	$34.7M-0.6%	$34.9M
Current Liabilities	$28.6M-0.3%	$28.7M-5.3%	$30.3M-21.2%	$38.4M+5.3%	$36.4M+139.5%	$15.2M+30.5%	$11.7M+16.4%	$10.0M
Long-Term Debt	$16.9M-9.8%	$18.7M+0.4%	$18.7M	$0	$0-100.0%	$20.8M-8.9%	$22.8M-8.2%	$24.9M
Total Equity	-$6.6M-347.7%	$2.7M-75.9%	$11.1M-39.5%	$18.3M-39.0%	$30.0M-26.4%	$40.8M-20.2%	$51.1M-16.3%	$61.1M
Retained Earnings	-$295.5M-3.7%	-$284.9M-3.6%	-$275.1M-3.4%	-$265.9M-5.5%	-$252.2M-5.3%	-$239.6M-5.5%	-$227.1M-5.7%	-$214.9M

VIRX Cash Flow Statement

Metric	FY23	FY22	FY21	FY20	FY19	FY18
Operating Cash Flow	-$39.9M-12.5%	-$35.5M-88.1%	-$18.9M-17.4%	-$16.1M-54.7%	-$10.4M+57.5%	-$24.4M
Capital Expenditures	$138K+206.7%	$45K-82.1%	$252K+358.2%	$55K	N/A	N/A
Free Cash Flow	-$40.0M-12.8%	-$35.5M-85.8%	-$19.1M-18.6%	-$16.1M	N/A	N/A
Investing Cash Flow	$15.0M+127.8%	-$53.9M-517.9%	$12.9M+23538.2%	-$55K	$0-100.0%	$4.8M
Financing Cash Flow	$438K-98.1%	$22.5M-63.9%	$62.4M+38.8%	$45.0M+83.0%	$24.6M+287.6%	$6.3M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22
Operating Cash Flow	-$7.1M+27.8%	-$9.8M-25.2%	-$7.8M+21.7%	-$10.0M+4.8%	-$10.5M-31.9%	-$8.0M+29.5%	-$11.3M-43.5%	-$7.9M
Capital Expenditures	$0	N/A	N/A	$0+100.0%	-$51K	N/A	N/A	$0
Free Cash Flow	-$7.1M	N/A	N/A	-$10.0M+5.3%	-$10.6M	N/A	N/A	-$7.9M
Investing Cash Flow	$8.2M-30.3%	$11.7M-17.5%	$14.2M+53.1%	$9.3M+1.9%	$9.1M+128.6%	$4.0M+154.1%	-$7.3M-3520.7%	-$203K
Financing Cash Flow	-$1.9M-4567.4%	$43K+100.7%	-$6.6M-3126.6%	$218K	$0-100.0%	$204K+1175.0%	$16K-99.9%	$21.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

VIRX Financial Ratios

Metric	FY23	FY22	FY21	FY20	FY19	FY18
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	-15679.2%-14555.8pp	-1123.4%+9724.7pp	-10848.1%
Net Margin	N/A	N/A	N/A	-15847.5%-15193.4pp	-654.1%+10575.9pp	-11230.0%
Return on Equity	-278.7%-198.2pp	-80.5%+41.1pp	-121.6%	N/A	N/A	N/A
Return on Assets	-90.1%-38.8pp	-51.2%+54.5pp	-105.7%-66.3pp	-39.4%+34.1pp	-73.5%+100.2pp	-173.7%
Current Ratio	1.43-7.9	9.36-2.2	11.59+4.1	7.51-0.1	7.64+6.3	1.34
Debt-to-Equity	0.00-0.4	0.41+0.4	0.05+0.1	-0.09+1.6	-1.65+0.3	-1.97
FCF Margin	N/A	N/A	N/A	-13424.2%	N/A	N/A

Metric	Q3'24	Q2'24	Q1'24	Q4'23	Q3'23	Q2'23	Q1'23	Q4'22
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	-368.0%-285.5pp	-82.5%	N/A	-42.0%-11.4pp	-30.6%-6.7pp	-23.9%	N/A
Return on Assets	-48.1%-16.7pp	-31.4%-9.3pp	-22.1%	N/A	-19.0%-2.7pp	-16.2%-2.0pp	-14.2%	N/A
Current Ratio	0.76-0.3	1.08-0.3	1.35-0.1	1.43-0.3	1.77-3.1	4.90-2.3	7.16-2.2	9.36
Debt-to-Equity	-2.56-9.6	7.02+5.3	1.69+1.7	0.000.0	0.00-0.5	0.51+0.1	0.45+0.0	0.41
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Altamira Therapeutics Ltd CYTOF

$286K

Bio-Path Hldgs Inc BPTH

$4.7M

Therapeutic Solutions Intl Inc TSOI

$512K

Respirerx Pharma RSPI

$849K

Panbela Therapeutics Inc PBLA

$243K

Frequently Asked Questions

Is Viracta Therapeutics Inc profitable?

No, Viracta Therapeutics Inc (VIRX) reported a net income of -$51.1M in fiscal year 2023.

What is Viracta Therapeutics Inc's EBITDA?

Viracta Therapeutics Inc (VIRX) had EBITDA of -$50.2M in fiscal year 2023, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Viracta Therapeutics Inc have?

As of fiscal year 2023, Viracta Therapeutics Inc (VIRX) had $12.3M in cash and equivalents against $0 in long-term debt.

What is Viracta Therapeutics Inc's return on equity (ROE)?

Viracta Therapeutics Inc (VIRX) has a return on equity of -278.7% for fiscal year 2023, measuring how efficiently the company generates profit from shareholder equity.

What is Viracta Therapeutics Inc's free cash flow?

Viracta Therapeutics Inc (VIRX) generated -$40.0M in free cash flow during fiscal year 2023. This represents a -12.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Viracta Therapeutics Inc's operating cash flow?

Viracta Therapeutics Inc (VIRX) generated -$39.9M in operating cash flow during fiscal year 2023, representing cash generated from core business activities.

What are Viracta Therapeutics Inc's total assets?

Viracta Therapeutics Inc (VIRX) had $56.7M in total assets as of fiscal year 2023, including both current and long-term assets.

What are Viracta Therapeutics Inc's capital expenditures?

Viracta Therapeutics Inc (VIRX) invested $138K in capital expenditures during fiscal year 2023, funding long-term assets and infrastructure.

How much does Viracta Therapeutics Inc spend on research and development?

Viracta Therapeutics Inc (VIRX) invested $33.4M in research and development during fiscal year 2023.

How many shares does Viracta Therapeutics Inc have outstanding?

Viracta Therapeutics Inc (VIRX) had 39M shares outstanding as of fiscal year 2023.

What is Viracta Therapeutics Inc's current ratio?

Viracta Therapeutics Inc (VIRX) had a current ratio of 1.43 as of fiscal year 2023, which is considered adequate.

What is Viracta Therapeutics Inc's debt-to-equity ratio?

Viracta Therapeutics Inc (VIRX) had a debt-to-equity ratio of 0.00 as of fiscal year 2023, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Viracta Therapeutics Inc's return on assets (ROA)?

Viracta Therapeutics Inc (VIRX) had a return on assets of -90.1% for fiscal year 2023, measuring how efficiently the company uses its assets to generate profit.

What is Viracta Therapeutics Inc's cash runway?

Based on fiscal year 2023 data, Viracta Therapeutics Inc (VIRX) had $12.3M in cash against an annual operating cash burn of $39.9M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Viracta Therapeutics Inc's Piotroski F-Score?

Viracta Therapeutics Inc (VIRX) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Viracta Therapeutics Inc's earnings high quality?

Viracta Therapeutics Inc (VIRX) has an earnings quality ratio of 0.78x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Viracta Therapeutics Inc cover its interest payments?

Viracta Therapeutics Inc (VIRX) has an interest coverage ratio of -13.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.